Abcam (ABC) PT Raised to GBX 1,100 at Peel Hunt
Abcam (LON:ABC) had its target price hoisted by research analysts at Peel Hunt from GBX 1,020 ($13.83) to GBX 1,100 ($14.92) in a note issued to investors on Monday. The firm presently has a “hold” rating on the stock. Peel Hunt’s target price indicates a potential downside of 3.42% from the stock’s previous close.
Several other analysts have also recently weighed in on ABC. JPMorgan Chase & Co. boosted their price objective on Abcam from GBX 864 ($11.72) to GBX 946 ($12.83) and gave the stock a “neutral” rating in a report on Monday, September 18th. Numis Securities raised Abcam to a “buy” rating and set a GBX 1,200 ($16.27) price objective for the company in a report on Friday, January 5th. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 1,240 ($16.82) price objective on shares of Abcam in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of GBX 1,009.33 ($13.69).
Shares of Abcam (ABC) opened at GBX 1,139 ($15.45) on Monday. The firm has a market capitalization of $2,330.00 and a PE ratio of 5,423.81. Abcam has a twelve month low of GBX 9.73 ($0.13) and a twelve month high of GBX 1,170.98 ($15.88).
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.